Purpose: This non-interventional study was conducted to evaluate the efficacy and tolerability of intravenous lacosamide (LCM-iv) under routine conditions in daily clinical practice as a prospective registry. Methods: Patients with any type of seizure or epilepsy syndrome were recruited in 16 neurological and neuropediatric centers in Germany if the treating physician decided to administer LCM-iv for any reason. Observation time per patient was 10 days with daily documentation of LCM-iv administration, type and frequency of seizures, currently used drugs and doses, and adverse events. Treatment efficacy, tolerability, and handling of LCM-iv were assessed using a five-step scale. Results: In 119 patients treating physicians classified epilepsies as focal in 66.1% and generalized in 17.4% (16.5% unclassifiable). Most common etiologies of seizures were tumors (36.1%) and cerebrovascular diseases (21.8%). Reasons for LCM-iv treatment included preparation for surgery (25.2%), convulsive (24.4%) and non-convulsive (18.5%) status epilepticus (SE), series of seizures (16.0%), gastrointestinal causes (5.9%), and acute seizures (4.2%). The median dose of LCM-iv was 300 mg per day. In 45 of 64 patients (70.3%) with SE or series of seizures, epileptic activity ceased during observation time. Five patients showed abnormalities in ECG prior to the infusion and one patient afterwards, but during infusion no abnormalities were reported. Treating physicians rated efficacy and tolerability as very good or good in 77.6% and 93.1% of patients, respectively. Conclusions: This large and independent multicenter registry on the use of LCM-iv in clinical practice demonstrates that LCM-iv is well-tolerated and highly efficacious when given in emergency situations, including patients experiencing SE. It is advisable to perform an electrocardiogram prior to LCM-iv administration.
Introduction
Lacosamide (LCM) is an antiepileptic drug (AED) that enhances sodium channel slow activation. LCM is indicated as adjunctive treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older in the EU, respectively 17 years and older in the US. The efficacy and tolerability of oral LCM added to existing AED therapy has been established in numerous studies. [1] [2] [3] Since its introduction to the market in 2008, many patients with therapy-resistant partialonset seizures have been treated successfully. LCM is characterized by a favorable pharmacokinetic profile with low protein binding and no effect on the plasma concentrations of concomitantly administered AEDs. 4, 5 In order to meet the need to provide the drug for patients in emergency situations who are temporarily unable to swallow, intravenous LCM (LCM-iv) was developed and approved as replacement therapy for oral LCM in patients with partial-onset seizures. 6, 7 In consequence of its favorable pharmacokinetic profile, the intravenous formulation is of interest for the treatment of status epilepticus (SE) as well 8 ; however, LCM is not licensed for this indication. Nevertheless, several case reports and observational studies have shown encouraging results with LCM-iv in SE [9] [10] [11] [12] [13] , indicating that LCM-iv may be a useful alternative in the treatment of SE. Accordingly, national guidelines recommend considering the use of LCM-iv in case earlier lines such as benzodiazepines, phenytoin, valproate, levetiracetam, or phenobarbital are contraindicated or fail to produce a response in the patient. 14 In order to explore the spectrum of LCM-iv application in daily use and to evaluate the efficacy and tolerability of LCM given intravenously under routine practice conditions, the present prospective non-interventional study was conducted as an independent registry over an observational period of 10 days.
Methods

Study design
The study was designed as a prospective non-interventional observational trial (according to §67.6 AMG [German Medicinal Products Act]) in 16 neurological and neuropediatric centers in Germany from July 2011 to October 2013. Observation time per patient was 10 days with daily documentation. The study was approved by the institutional ethic committees of all participating centers and was carried out according to the Declaration of Helsinki and local health regulations. Written informed consent was obtained from patients before enrolment in the study. If patients were unable to give consent, it was requested from their legal guardian or close relatives. Patients were free to withdraw from the study at any time and for any reason. Treatment, including diagnosis and control, was restricted to medical practice and did not follow any predefined study plan or interventions. No diagnostic or therapeutic measures, exceeding the already necessary scope were required and treatment routine was not altered by this non-interventional, observational study.
Patients
Patients with any type of seizures or epilepsy syndrome were selected if the treating physician decided to administer LCM-iv for any reason, e.g. previous treatment results were unsatisfactory, anticonvulsant therapy with LCM-iv was preferred and/or surgical intervention with anesthesia did not allow oral LCM treatment. Criteria for non-selection included hypersensitivity to the active substance or to any of the excipients listed in the summary of product characteristics. Patients were selected at the discretion of the investigator. To minimize bias, the physician was obliged to include and to document consecutively the first appropriate patients fitting the selection criteria defined in the study protocol. Administration of LCM-iv was given as assigned by the treating physician; the summary of product characteristics recommended infusion over a period of 15-60 min twice daily whereby the recommended starting dose was 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response and tolerability, the maintenance dose could be further increased by 50 mg twice a day every week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). Conversion to or from oral and intravenous administration could be executed directly without titration. The physician determined whether baseline AEDs were modified.
Safety and efficacy assessments
Baseline demographics and disease characteristics as well as previous and current AED use were recorded in the Case Report Form (CRF). Seizure frequency and seizure types were captured during a 4-week retrospective baseline period. Seizures were classified according to the International League against Epilepsy (ILAE) classification. Status epilepticus was defined as ongoing seizures or seizures without recovery of consciousness or clinical baseline conditions for at least 30 minutes.
Daily documentation included LCM-iv administration, type and frequency of the seizures, currently used drugs and doses, and adverse events (AEs). Measurements of blood pressure, pulse, and electrocardiograms (ECG) were performed prior, during and after the LCM infusion. At study end, overall treatment efficacy and tolerability were assessed by patients and physicians using a fivestep scale (very good, good, satisfactory, sufficient, insufficient). Additionally, handling of LCM-iv and switching from oral to the intravenous formulation was assessed by physicians on a 5-step scale (very easy, easy, normal, difficult, very difficult).
Efficacy variables were physician's (primary endpoint) and patient's assessment of efficacy, changes in seizure frequency and type, and resolution of any SE.
Statistical analyses
All data analyses were carried out according to a preestablished analysis plan. The sample size was chosen in order to gain a representative sample that would cover a broad range of seizure types and allow the discovery of rare adverse drug reactions. The collected data were analyzed with epidemiological methods, using SAS (SAS Institute Inc., Cary, NC, USA). For continuous variables, statistic parameters including arithmetic mean, median, standard deviation, and range were calculated. Frequency distributions for discrete variables were provided as percentage in relation to the total sample. Free text answers were transferred post hoc into adequate coding schemes and analyzed as frequency distribution. Adverse events were coded according to the Medical Dictionary for Regulatory Activities. Missing values were not imputed. Post-hoc, a subgroup analysis was performed for patients with SE, including those featuring convulsive SE, nonconvulsive SE and seizure series.
Results
Patient disposition and baseline characteristics
LCM-iv was started in 130 patients, which comprised the safety set. Eleven patients were excluded from the efficacy analysis due to lack of sufficient outcome data, including seizure outcome. The remaining 119 patients were included in the efficacy set. Baseline characteristics are summarized in Table 1 . Patients had epilepsy for a median duration of 10 days (range 1-10,751 days). Most frequent etiologies of epilepsy were tumors (36.1%) and cerebrovascular events (21.8%). Overall, 107 patients (89.9%) had at least one concomitant disease in addition to nervous system disorders, most frequently vascular disorders (37.0%), neoplasms (32.8%), and metabolic disorders (21.0%). Fifty-five patients (46.2%) had received at least one pretreatment, predominantly AEDs (42.9%), and psycholeptics (31.1%). Reasons for the treatment with LCM-iv are summarized in Table 2 . Thirty-nine of 51 patients had first time SE. Duration of SE before LCM-iv administration was <24 h in 21.6%, 24h-3d in 43.1%, 3-10d in 23.5%, and >10d in 11.8% of SE patients. The acute triggers for seizures were known for 19 patients: fever occurred most frequently (N = 8), followed by dehydration (N = 4), acute brain injury (N = 2), hyponatremia (N = 2), encephalitis (N = 2), and lack of medication compliance (N = 1).
Treatment with LCM-iv
The median dose of LCM-iv was 300 mg (range 93-1200 mg) per day administered in a median number of 4.0 (range 1-29) infusions. Median duration of LCM-iv treatment was 2 days (range 1.0-10.0 days). Physicians used 0.9% saline solution as carrier in the majority of patients (94.1%). Almost all patients (98.3%) received at least one additional medication, mostly AEDs (97.5%).
In 26.1% of patients the additional medication was administered with the infusion. Ten patients (8.4%) had already been treated with oral LCM prior to the study start. At study end, 74 patients (62.2%) continued treatment with LCM whereof 68 patients switched to the oral formulation and six continued intravenous administration.
For pulse rate, diastolic and systolic blood pressure no clinically relevant changes over the infusion period were reported (Table 3) . Five patients showed abnormalities in ECG prior to the infusion and one patient afterwards, but during infusion no abnormalities were reported (Table 3) .
The adjustment from oral to intravenous administration and vice versa was manageable without difficulties. Similarly, none of the treating physicians reported any difficulties in handling the intravenous administration of LCM.
Efficacy
Investigators rated the efficacy of LCM-iv as good or very good for the majority of patients (77.6%). According to the patients' assessment, efficacy was good or very good in 87.9% of cases (Fig. 1) . In 45 (70.3%) of 64 patients with SE or series of seizures, seizure activity ceased in close temporal relation to administration of LCM-iv.
Tolerability
Treating physicians rated the tolerability of LCM-iv for 93.1% of patients as good or very good. This was in accordance with the assessment by the patients of whom 94.5% rated tolerability as good or very good (Fig. 2) . In total, 21 treatment emergent adverse events (TEAE) were reported in 17 patients (13.1%). Of those, 13 TEAE in 10 patients (7.7%) were serious. The treating physicians assessed ten TEAE in seven patients (5.4%) as at least possibly related to LCM-iv (Table 4) . Of those, six TEAE in three patients (2.3%) were serious (bronchial secretion retention, bronchopneumonia, drug ineffective, complete atriventricular block, second degree atriventricular block, cardiac arrest). At the time of reporting, five patients had recovered, one patient (bronchial secretion retention and bronchopneumonia) was not yet recovered, and information on the outcome was unavailable for one patient (drug ineffective). Three patients died during the observation period (causes of death: pulmonary embolism, meningeal carcinomatosis from breast cancer, liver cirrhosis), but none of the deaths was related to the study drug. Fourteen patients (11.8%) discontinued LCM-iv prematurely during the observation period due to insufficient effect (N = 4), ADR, death (N = 2), switch in medication (N = 5), patient request, or poor vein conditions.
Discussion
The present non-interventional study explored the spectrum of LCM-iv application in daily use as well as efficacy and tolerability of the intravenous formulation over an observational period of 10 days. Although LCM-iv is not approved for SE, its use may be considered in accordance with national guidelines when earlier lines are contraindicated or fail to produce a response in the patient.
14 SE requires emergent, targeted treatment to reduce patient morbidity and mortality. As such, LCM provides a rapid onset of effect due to quick occurrence of peak plasma levels within one to four hours after administration and high bioavailability of approximately 100%. 15 Based on this rationale, the patient population evaluated in this study included 51 patients with SE and 19 patients with a series of seizures. Shortly after administration of LCM-iv, seizure activity ceased in 70% of these 64 patients, indicating high efficacy in patients with SE or series of seizures. To date no randomized controlled trials have been conducted to investigate the use of LCM-iv in SE. However, our data confirm results from previous case reports and observational studies that emerged after promising results had been obtained in rodent models of SE. 16, 17 The first experience in humans regarding the effect of LCM-iv on SE was achieved in a patient with nonconvulsive SE. Intravenous administration of LCM resulted in complete cessation of the SE in combination with benzodiazepines that had been administered without effect 10 min before. 18 The first successful treatment of refractory convulsive SE was reported from Austria. After treatment failure with diazepam, etomidate, midazolam, lorazepam, and levetiracetam, further treatment with LCM-iv 300 mg resulted in complete clinical remission of the epileptic activity within 30 min. 19 A case series from a German center described seven patients with refractory focal SE that was terminated within 24 h after LCM administration. 10 Another case series demonstrated resolution of non-convulsive SE in seven out of 10 patients, while an eighth patient showed cessation of SE, but still experienced frequent electrographic seizures. 12 An observational study investigating nine patients who received LCM-iv after failure of at least two other agents produced conflicting results. While no patient experienced immediate resolution of refractory SE within four hours after LCM injection, a decrease in seizure frequency was observed in two patients in the days following the initiation of the combination LCM and phenytoin. Two other patients demonstrated improvement in EEG of their SE. 20 The largest case series to date demonstrating the successful use of LCM-iv in patients with non-convulsive SE and motor focal SE was obtained in a retrospective study conducted at a single center. Out of 92 patients, 67.7% responded to treatment, and an adjusted regression analysis indicated an independent association of LCM with cessation of SE. 21 Another retrospective analysis evaluated 48 patients with SE or seizure clusters. Cessation was observed in 88% of patients, whereby response rates corresponded to the time when LCM-iv was administered. The earlier LCM was used, the higher the response rate. 11 In a small prospective observational study nine of 25 patients (36%) with refractory SE and seizure clusters responded to LCM-iv. Higher response rates were achieved with a loading dose of 400 mg LCM compared to 200 mg. 22 Concordantly, in a larger multicenter prospective study 64.7% of refractory SE patients demonstrated response to LCM-iv treatment, whereby the majority (82.4%) of this population had focal convulsive SE. 13 A retrospective observational study conducted in Spain indicated that LCM-iv was mainly used in patients with non-convulsive SE. 70.9% of SE patients obtained seizure cessation after LCM-iv administration. 23 Our prospective data with an equally high response rate of 70% provide additional evidence for the use of LCM-iv in patients with convulsive and non-convulsive SE. Accordingly, efficacy was predominantly rated good or very good by physicians and patients alike. The high response rate might be attributable to the mechanism of action that differentiates LCM from other AEDs. In contrast to traditional sodium channel blockers (e.g. carbamazepine, oxcarbazepine, lamotrigine and phenytoin) which primarily affect fast inactivation, LCM enhances sodium channel slow inactivation. 24 In line with previous observations LCM-iv was well tolerated. Adverse drug reactions were rare and mostly transient. The three deaths reported during the observation period had no relation to LCM-iv but were attributed to the underlying disease. No significant abnormalities in blood pressure, pulse rate and ECG were observed during the infusion. The TEAEs bronchial secretion retention, bronchopneumonia and cardiac arrest are not mentioned in the summary of product characteristics as common side effects of lacosamide. The treating physicians assessed the causal relationship of bronchial secretion retention and bronchopneumonia as probable and that of cardiac arrest as possible. The study included five patients aged 16 years who received LCM-iv in the course of an emergency situation although LCM is not approved for this age group. None of these patients experienced any adverse events. The overall safety assessment suggests that LCM-iv is well tolerated in a patient population of different ages, including children and elderly. The study is limited by its non-interventional design, which did not allow a wash-out phase before administration of LCM-iv was initiated. For ethical reasons, a wash-out phase is not to be recommended either. The lack of a control group and the use of concomitant AEDs might interfere with the interpretation of outcome data. Therefore, causality cannot be concluded. However, the large number of patients responding to treatment after failure of previous AEDs ensures statistically conclusive data to assume that the observed effects may be attributable to LCM-iv. Overall, the study design was chosen to provide a comprehensive profile of the use of LCM-iv in a real-world setting.
Conclusions
Data from this large registry on the use of intravenous lacosamide suggest that LCM-iv is well-tolerated and has high efficacy also in status epilepticus. Furthermore, the administration of LCM-iv was convenient and the switch from the oral to the intravenous formulation did not require dose adjustments. In corroboration of previous case reports, our results support the use of LCM-iv as alternative treatment option in SE. In this regard, even in emergency situations caution advises to perform rapid ECG diagnostics prior to LCM-iv administration in order to rule out second-or third-degree atrioventricular block, a known contraindication of LCM that may lead to prolongation of the PR interval. 14 Although current guidelines recommend a starting dose of 5 mg/ kg 14 , it might be useful to consider treatment initiation on a higher dose such as 10 mg/kg, in order to achieve more effective serum concentrations in a shorter period of time. Yet, to date, there are no safety data available regarding this approach. Randomized trials are required in order to confirm the observed beneficial effects of LCM-iv in the treatment of SE under controlled conditions.
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